Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | FPR1 | P21462 | 2/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156707 | 0.90 | KDM1A (0.47) | FPR1KDM1AMAPTPKMCHRM1 | |
| SCHEMBL5156105 | 0.87 | ALDH1A1 (0.43) | TACR1FPR1MAPTPKMALDH1A1 | |
| SCHEMBL5159699 | 0.83 | MAPT (0.38) | TACR1FPR1KDM1AMAPTPKM | |
| SCHEMBL5161860 | 0.82 | MAPT (0.47) | FPR1KDM1AMAPTPKMALDH1A1 | |
| SCHEMBL5176925 | 0.81 | KDM1A (0.46) | FPR1KDM1AMAPTPKM | |
| SCHEMBL5161629 | 0.78 | KDM1A (0.42) | FPR1KDM1AMAPTPKMALDH1A1 | |
| SCHEMBL6482545 | 0.78 | KDM1A (0.43) | FPR1KDM1AMAPTPKMALDH1A1 | |
| SCHEMBL5161850 | 0.77 | KDM1A (0.43) | FPR1KDM1AMAPTPKM | |
| SCHEMBL5161368 | 0.77 | GRM7 (0.48) | FPR1KDM1AMAPTPKM | |
| SCHEMBL5158998 | 0.74 | SSTR4 (0.53) | FPR1KDM1AMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | TACR1 2/4885FPR1 607/4885MMP1 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.